AIM ImmunoTech Inc (AMEX:AIM) has a beta value of -0.29 and has seen 0.53 million shares traded in the recent trading session. The company, currently valued at $14.83M, closed the recent trade at $0.23 per share which meant it lost -$0.02 on the day or -6.79% during that session. The AIM stock price is -169.57% off its 52-week high price of $0.62 and 30.43% above the 52-week low of $0.16. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.75 million shares traded. The 3-month trading volume is 500.41K shares.
The consensus among analysts is that AIM ImmunoTech Inc (AIM) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.09.
AIM ImmunoTech Inc (AMEX:AIM) trade information
Sporting -6.79% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the AIM stock price touched $0.23 or saw a rise of 8.0%. Year-to-date, AIM ImmunoTech Inc shares have moved 17.46%, while the 5-day performance has seen it change 10.74%. Over the past 30 days, the shares of AIM ImmunoTech Inc (AMEX:AIM) have changed 13.39%. Short interest in the company has seen 0.49 million shares shorted with days to cover at 1.63.
AIM ImmunoTech Inc (AIM) estimates and forecasts
Figures show that AIM ImmunoTech Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -35.42% over the past 6 months, with this year growth rate of 50.00%, compared to 16.70% for the industry. Revenue growth from the last financial year stood is estimated to be -0.99%.
1 analysts offering their estimates for the company have set an average revenue estimate of 100k for the current quarter. Year-ago sales stood 65k and 40k respectively for this quarter and the next, and analysts expect sales will grow by 53.85% for the current quarter and -0.99% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 42.86% over the past 5 years.
AIM Dividends
AIM ImmunoTech Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
AIM ImmunoTech Inc (AMEX:AIM)’s Major holders
Insiders own 8.57% of the company shares, while shares held by institutions stand at 14.07% with a share float percentage of 15.39%. Investors are also buoyed by the number of investors in a company, with AIM ImmunoTech Inc having a total of 33.0 institutions that hold shares in the company. The top two institutional holders are ARMISTICE CAPITAL, LLC with over 4.08 million shares worth more than $1.52 million. As of 2024-06-30, ARMISTICE CAPITAL, LLC held 8.2454% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 1.99 million shares as of 2024-06-30. The firm’s total holdings are worth over $0.74 million and represent 4.021% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 2.06% shares in the company for having 1.31 shares of worth $0.31 million while later fund manager owns 620.23 shares of worth $0.15 million as of Sep 30, 2024 , which makes it owner of about 0.97% of company’s outstanding stock.
